In vitro antiviral activity and preliminary clinical trials of a new adamantane compound.
A compound, 1'-methyl spiro (adamantane-2,3'-pyrrolidine) maleate, chemically related to the antiviral drug amantadine, was tested for activity in vitro against a number of human respiratory viruses. By a variety of techniques, it was shown to be active against a wide range of human and animal influenza A viruses. The effect was, however, variable and ranged from high activity against two 1957 Asian strains to no observable activity against a 1971 strain. Like amantadine, the drug did not inhibit the growth of influenza B viruses. It was also inactive against a number of paramyxoviruses. Unlike amantadine, the drug did inhibit rhinoviruses, but to a lesser extent than myxoviruses. The coronavirus 229E was also sensitive to the action of the drug in vitro. Although an earlier trial in volunteers showed that, when given orally from 2 days before until 5 days after virus challenge, the drug was protective against infection with influenza A/Hong Kong/68 virus, a similar trial in volunteers challenged with rhinoviruses 2 and 9 revealed no useful activity against rhinoviruses in man.
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D002642:Chick Embryo; D003516:Cycloparaffins / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D009975:Orthomyxoviridae / Q000187:drug effects; D011759:Pyrrolidines / Q000627:therapeutic use; D018108:Respirovirus / Q000187:drug effects; D012229:Rhinovirus / Q000187:drug effects; D014780:Viruses / Q000187:drug effects*
D000998:Antiviral Agents; D001952:Bridged-Ring Compounds; D003516:Cycloparaffins; D011759:Pyrrolidines